Tags

Type your tag names separated by a space and hit enter

Recent advances in continuous glucose monitoring.
Exp Clin Endocrinol Diabetes. 2001; 109 Suppl 2:S347-57.EC

Abstract

Continuous glucose monitoring, providing more detailed information on glucose excursions than single spot measurements, should help to improve the therapy in diabetic patients and is also required for feedback-controlled insulin delivery. At the Institute for Diabetes-Technology in Ulm, founded by EF Pfeiffer, a portable glucose sensor for continuous tissue glucose monitoring has been developed. The combination of microdialysis and enzymatic amperometric glucose measurement implemented in this device marked a break-through in achieving reliable and precise continuous tissue glucose monitoring. In several studies, we have demonstrated that continuous subcutaneous glucose monitoring for up to 72 hours is feasible under 'in-house' and 'daily life' conditions in diabetic patients. The measured tissue glucose concentrations correlated closely to glucose control measurements in venous and capillary blood. A reliable continuous glucose monitoring device is a prerequisite for the development of an artificial pancreas. Our group developed an algorithm for subcutaneous application of the fast acting insulin analogon lispro. In experiments performed over 7 and 24 hours good metabolic control was achieved by algorithm-based insulin application. In addition, the algorithm was able to maintain acceptable metabolic control during and after moderate physical exercise. Further work is needed to optimize continuous tissue glucose monitoring systems and to develop a closed loop system for insulin application based on continuously measured tissue glucose concentrations.

Authors+Show Affiliations

Institute for Diabetes-Technology, University of Ulm, Germany. guido.freckmann@medizin.uni-ulm.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11460583

Citation

Freckmann, G, et al. "Recent Advances in Continuous Glucose Monitoring." Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association, vol. 109 Suppl 2, 2001, pp. S347-57.
Freckmann G, Kalatz B, Pfeiffer B, et al. Recent advances in continuous glucose monitoring. Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S347-57.
Freckmann, G., Kalatz, B., Pfeiffer, B., Hoss, U., & Haug, C. (2001). Recent advances in continuous glucose monitoring. Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association, 109 Suppl 2, S347-57.
Freckmann G, et al. Recent Advances in Continuous Glucose Monitoring. Exp Clin Endocrinol Diabetes. 2001;109 Suppl 2:S347-57. PubMed PMID: 11460583.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Recent advances in continuous glucose monitoring. AU - Freckmann,G, AU - Kalatz,B, AU - Pfeiffer,B, AU - Hoss,U, AU - Haug,C, PY - 2001/7/20/pubmed PY - 2002/1/5/medline PY - 2001/7/20/entrez SP - S347 EP - 57 JF - Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association JO - Exp Clin Endocrinol Diabetes VL - 109 Suppl 2 N2 - Continuous glucose monitoring, providing more detailed information on glucose excursions than single spot measurements, should help to improve the therapy in diabetic patients and is also required for feedback-controlled insulin delivery. At the Institute for Diabetes-Technology in Ulm, founded by EF Pfeiffer, a portable glucose sensor for continuous tissue glucose monitoring has been developed. The combination of microdialysis and enzymatic amperometric glucose measurement implemented in this device marked a break-through in achieving reliable and precise continuous tissue glucose monitoring. In several studies, we have demonstrated that continuous subcutaneous glucose monitoring for up to 72 hours is feasible under 'in-house' and 'daily life' conditions in diabetic patients. The measured tissue glucose concentrations correlated closely to glucose control measurements in venous and capillary blood. A reliable continuous glucose monitoring device is a prerequisite for the development of an artificial pancreas. Our group developed an algorithm for subcutaneous application of the fast acting insulin analogon lispro. In experiments performed over 7 and 24 hours good metabolic control was achieved by algorithm-based insulin application. In addition, the algorithm was able to maintain acceptable metabolic control during and after moderate physical exercise. Further work is needed to optimize continuous tissue glucose monitoring systems and to develop a closed loop system for insulin application based on continuously measured tissue glucose concentrations. SN - 0947-7349 UR - https://www.unboundmedicine.com/medline/citation/11460583/Recent_advances_in_continuous_glucose_monitoring_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2001-18594 DB - PRIME DP - Unbound Medicine ER -